Syndax's Revuforj Earns Strong Physician Support, JP Morgan Predicts Sales Growth

Important legal information about the email you will be sending. By using this service, you agree to input your real email address and only send it to people you know. It is a violation of law in some jurisdictions to falsely identify yourself in an email. All information you provide will be used by Fidelity solely for the purpose of sending the email on your behalf. The subject line of the email you send will be "Fidelity.com: "

Syndax's Revuforj Earns Strong Physician Support, JP Morgan Predicts Sales Growth

, Benzinga - 12:56 PM ET 3/21/2025 default

JP Morgan released a survey on Thursday focused on the launch prospects of Syndax Pharmaceuticals Inc’s Revuforj (revumenib) in relapsed/refractory (r/r) KMT2A acute leukemias and nucleophosmin 1 mutation acute myeloid leukemia (NPM1 AML).

The FDA approved Revuforj in November 2024 as the first and only menin inhibitor for r/r acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and pediatric patients one year and older.

Revuforj generated $7.7 million in net product revenue during its first five weeks on the market.

The company expects to submit a supplemental application filing for revumenib in R/R mNPM1 AML in the second quarter of 2025, followed by a potential FDA approval around year-end 2025.

Also Read: FDA Approves Incyte/Syndax Partnered Drug For Chronic Graft-Versus-Host Disease, A Post-Transplant Complication

JPMorgan says that, on average, surveyed physicians treated 8 KMT2A acute leukemia and 12 NPM1 AML patients.

Overall, surveyed physicians provided high ratings related to Revuforj’s clinical profile in both r/r KMT2A acute leukemias and NPM1 AML.

Analyst Anupam Rama writes that surveyed physicians indicated a high degree of comfort using Revuforj in r/r NPM1 should the product be incorporated into NCCN guidelines.

“In our view, survey results underscore that SNDX shares are currently materially undervalued on Revuforj in the r/r (KMT2A / NPM1) setting alone – which we value in the ~high-$20 to low-$30s / share range,” Rama writes.

For the near term, JPMorgan estimates 2025 Revuforj sales to be around $50 million (US only), largely driven by the KMT2A setting.

JPMorgan raised its price target from $39 to $41, accounting for a faster ramp to peak for Revuforj in both KMT2A acute leukemias and NPM1 AML, reiterating the Overweight rating.

Price Action: SNDX stock is up 0.43% at $14.16 at last check Friday.

Read Next:

China, Hong Kong, And Europe Markets Dip; Dollar Strengthens – Global Markets Today While US Slept

Photo: Shutterstock